Moderna, Inc.

Valuation Analysis

About the Company

Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company's respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines. It also provides oncology therapeutics, such as intismeran autogene, cancer antigen therapy, t-cell engager, and cell therapy enhancer; and rare disease products, including propionic and methylmalonic acidemia, and cystic fibrosis. It has strategic alliances and c

Moderna, Inc. Stock at a Glance

Moderna, Inc. (MRNA) is currently trading at $49.91 with a market capitalization of $19.8B. The 52-week range spans from $22.28 to $59.55; the current price is 16.2% below the yearly high. Year-over-year revenue growth stands at +260.2%.

💰 Dividend

Moderna, Inc. currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Analyst Rating

20 analysts rate Moderna, Inc. (MRNA) on consensus: Hold. The average price target is $43.30, implying -13.24% from the current price. Analyst price targets range from $21.00 to $69.00.

Moderna, Inc.: The Investment Case in Detail

Moderna, Inc. (MRNA) operates in the Healthcare — specifically Biotechnology — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

The Bull Case

Top-line momentum is unusually strong with revenue expanding 260.2% year-over-year, a pace that puts the company well above the market average and signals genuine demand traction rather than mere cyclical tailwind.

The Bear Case

Net margins remain negative, meaning every euro of revenue is still producing losses — the path to profitability is the central question for shareholders. Short interest sits at 17.82% of float — a meaningful contingent of professionals is positioned for the share to fall, which deserves attention even if their thesis may turn out to be wrong.

Investment Thesis: Strengths & Weaknesses

Technical Snapshot

Price trades above both the 50- and 200-day moving averages, with 50d above 200d — a classic bullish setup (golden-cross alignment).

Risk Profile

The data points to market-like volatility, elevated short interest (17.82%).

Trading Data

Related Stocks in the Same Sector

Where can I buy Moderna, Inc.?

Compare top-rated brokers — low fees, trusted providers, fully regulated.